Roche to acquire US-based Poseida Therapeutics
26/11/2024 06:21
BERLIN, Nov 26 (Reuters) - Roche ROG.S will acquire
California-based biopharmafirm Poseida Therapeutics PSTX.O for
$9 per share at closing, for a total equity value of $1 billion,
the Swiss company said on Tuesday.
Stockholders will also receive a non-tradeable contingent
value right (CVR) for $4 per share, representing a total deal
value of up to approximately $1.5 billion, said the company.
The transaction is expected to close in the first quarter of
2025.
(Writing by Miranda Murray; Editing by Tom Hogue)
((Miranda.Murray@thomsonreuters.com;))